Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”
The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging
October 17, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the